Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0L2UQ
|
|||
| Former ID |
DNCL003496
|
|||
| Drug Name |
Pracinostat
|
|||
| Synonyms |
Pracinostat; 929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60] | Phase 3 | [1], [2] | |
| Myelodysplastic syndrome [ICD-11: 2A37] | Phase 2 | [3], [4] | ||
| Myelofibrosis [ICD-11: 2A20.2; ICD-10: D47.4] | Phase 2 | [3], [4] | ||
| Company |
MEI Pharma
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H30N4O2
|
|||
| Canonical SMILES |
CCCCC1=NC2=C(N1CCN(CC)CC)C=CC(=C2)C=CC(=O)NO
|
|||
| InChI |
1S/C20H30N4O2/c1-4-7-8-19-21-17-15-16(10-12-20(25)22-26)9-11-18(17)24(19)14-13-23(5-2)6-3/h9-12,15,26H,4-8,13-14H2,1-3H3,(H,22,25)/b12-10+
|
|||
| InChIKey |
JHDKZFFAIZKUCU-ZRDIBKRKSA-N
|
|||
| CAS Number |
CAS 929016-96-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
104253187, 121142796, 124757307, 125164111, 131480903, 134964553, 135264258, 136340267, 136359913, 136367450, 136920413, 137055167, 137390461, 140705810, 152258538, 160647372, 162011419, 162037638, 162202712, 163668154, 164193974, 172659608, 174520548, 174531534, 185973726, 188899586, 198945398, 202535654, 223366695, 223388553, 223705232, 227106278, 251963214, 252110018, 252160441, 252166577, 252216278, 252451771
|
|||
| ChEBI ID |
CHEBI:95071
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Histone deacetylase (HDAC) | Target Info | Modulator | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8365). | |||
| REF 4 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026393) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.